{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 42,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes before/after MRI scans for two specific patient cases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/23",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Data as of 8 August 2023. CNS, central nervous system; CR, complete response; NSCLC, Non-small cell lung cancer; PR, partial response; QD, once daily; TKI, tyrosine kinase inhibitor. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8c22902-f342-48a1-93f4-bdd8a11f98af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.425,
        "w": 0.212,
        "x": 0.258,
        "y": 0.358
      },
      "kind": "image",
      "text": "MRI scans showing baseline and 12 weeks for complete response case",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb1810d4-8938-46db-a34f-dd678a992d5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.425,
        "w": 0.212,
        "x": 0.727,
        "y": 0.358
      },
      "kind": "image",
      "text": "MRI scans showing baseline and 6 weeks for partial response case",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcb8aa3e-fe6b-4d1b-863c-2127c8ada379",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Intracranial Complete Response in EML4-ALK fusion NSCLC: EML4-ALK fusion NSCLC with no known ALK resistance mutations; 5 lines of therapy; NVL-655 (50 mg QD); Complete resolution of brain metastases after ~5 weeks; Treatment continues at 4.2 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88d6dd97-2dda-46ae-a5a7-efe53d249147",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Intracranial Partial Response in ALK L1196Q NSCLC: EML4-ALK fusion NSCLC with ALK L1196Q resistance mutation; 3 lines of therapy; NVL-655 (150 mg QD); CNS PR after ~6 weeks; Treatment continues at 3.7 months with ongoing confirmed CNS PR (-59%)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c56d9672-eef7-4983-9bf3-67043fe603e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "CNS Activity: NVL-655 Induced Intracranial Responses in Patients with TKI-Refractory ALK+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b036a59a-163a-42eb-9202-b83e05cc3d30",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}